SAB Biotherapeutics, Inc.

SAB Biotherapeutics (SABS) shows zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability on those dimensions. However, a clean recent period does not rule out material risks—the biotech sector faces persistent dilution pressure, financing volatility, and regulatory execution risk. Our full $49 Report extends the lookback to 12 months, quantifies dilution trajectory, maps financing history and runway, flags AI-detected risk signals in SEC language, and contextualizes any 8-K events within the company's capital structure. The full $49 Report adds dilution risk scoring, financing runway analysis, 12-month event history, and AI risk signals.